The Compound Report is an educational resource. Nothing on this site constitutes medical advice or encourages personal use of any compound. Always consult a qualified healthcare provider.
Educational reference only. Nothing on this page constitutes medical advice or encourages personal use of this compound. Always consult a qualified healthcare provider before any decision involving your health.
Effect demonstrated in multiple animal studies; human data sparse or extrapolated. Grades summarize evidence quality, not whether a compound is appropriate, legal, or risk-free.
Same compound, route-specific context. Switch forms instead of opening separate pages.
delivers Selank to olfactory neuroepithelium with direct access to limbic and prefrontal structures relevant to anxiety modulation. Rapid onset (10-30 minutes). The comm…
No route-matched protocol rows were parsed for this form; use the route notes and full dosing chapter before comparing options.
Open the full report at the dosing chapter for protocol rows, cycle context, and administration notes.
the compound studied in published clinical and preclinical research. Russian commercial formulation: 'Selank 0.15%' nasal drops (150 mcg per actuation), approved 2009. The compound in all referenced trials. This is what to use when 'Selank research' is the goal.
delivers Selank to olfactory neuroepithelium with direct access to limbic and prefrontal structures relevant to anxiety modulation. Rapid onset (10-30 minutes). The commercially approved Russian formulation uses 150 mcg per actuation. Community protocols range from 250-500 mcg per session.
Selank is the most credentialed research chemical in the Western peptide market and also the compound with the biggest gap between what its credentials imply and what independent science has confirmed. It is a registered pharmaceutical drug — in Russia. And that is a genuinely different evidentiary status than any other research peptide in this reference. It is also entirely from one country's development institutions, in one country's language, with one country's regulatory oversight. That is a meaningful distinction.
The central tension resolved: Selank's evidence is simultaneously the strongest of any neuropeptide in this reference (Russian Phase 2 clinical trial, regulatory approval, decades of clinical use data) and the weakest-validated by Western standards (zero independent replication, all evidence from development institutions, no English-language RCT in indexed literature). Both things are true. The community has evaluated this evidence and broadly concluded that the combination of consistent Russian clinical data, coherent mechanism, and individual experience is sufficient to justify use. That is a defensible position. It is not the same as 'proven by Western standards.'
The strongest argument for Selank: the clinical profile it offers — comparable anxiolytic efficacy to a benzodiazepine with none of the dependence, tolerance, sedation, or cognitive impairment — is genuinely without equivalent in Western pharmacology. If the Russian data is accurate (and there is no specific reason to doubt it beyond its provenance), Selank represents a therapeutic advance in anxiety management that the Western pharmaceutical industry has not replicated. The mechanism is coherent, the preclinical data is consistent, and the community experience over years of use has not produced safety signals.
The strongest argument for caution: the entire evidence base is from the people who developed and commercially benefit from Selank. Independent adversarial replication has not occurred. The FDA specifically flagged immunogenicity concerns and limited safety information for intranasal peptides. The WADA status is genuinely uncertain. And the mechanism — despite years of study — is still not fully characterized.
The default page keeps the decision layer visible first: summary, routes, evidence, and risks. Open the full report for mechanisms, chapter sections, citations, updates, and print/share controls.
Tuftsin → Selank → N-Acetyl Selank Amidate: Three Generations of Molecular Engineering. Russian-Approved Anxiolytic Without Sedation, Without Tolerance, Without Dependence. Comparable to Benzodiazepines for GAD With Psychostimulant Properties They Lack. BDNF Upregulation. Enkephalin Stabilization. The Evidence Is for Selank. NASA Is the More Stable Delivery Format Whose Equivalent Efficacy Is Chemically Logical but Clinically Unproven.
FDA-Approved at 50 mg for Opioid and Alcohol Use Disorder Since 1984. Off-Label at 1.5-4.5 mg (LDN) — Two Completely Different Mechanisms at Two Completely Different Doses. TLR4 Blockade on Microglia. The Endorphin Rebound. A Lancet Rheumatology RCT in 2024. An Evidence Base Growing Faster Than Pharma Has Any Reason to Fund. The Most Favorably Tolerated Prescription Drug in Its Evidence Literature.
Russia Uses It for Stroke. The West Uses It for Morning Focus. The Evidence Is Strong for One of Those. Guess Which.